CMA Letter to the Council of the Federation regarding the Council of the Federation meeting and Canada’s health funding priorities (health workforce, primary care, labour mobility)
https://policybase.cma.ca/link/policy14486

POLICY TYPE
Parliamentary submission

DATE
2022-06-22

TOPICS
Health systems, system funding and performance
Health human resources

Documents
CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities

https://policybase.cma.ca/link/policy14472

POLICY TYPE
Parliamentary submission

DATE
2022-03-28

TOPICS
Health human resources
Health systems, system funding and performance

Documents
Federal Policy Options to Advance Pan-Canadian Licensure

https://policybase.cma.ca/link/policy14471

POLICY TYPE
Parliamentary submission

DATE
2022-02-22

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents
**Study on Canada’s Health Workforce**

https://policybase.cma.ca/link/policy14469

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2022-02-16</td>
</tr>
</tbody>
</table>
| TOPICS               | Health systems, system funding and performance  
                        | Health human resources  
                        | Ethics and medical professionalism |

**Documents**

Appearance before the House of Commons Standing Committee on Health:

**Study on Canada’s Health Workforce**

Dr. Earlene Smart  
President of the Canadian Medical Association  
February 15, 2022  
Chaired by Hon. Wayne Easter

[Image of appearance before the House of Commons Standing Committee on Health]
Recommendations for federal action to address Canada’s health care crisis

https://policybase.cma.ca/link/policy14468

POLICY TYPE  Parliamentary submission
DATE  2022-02-15
TOPICS  Health systems, system funding and performance
         Health human resources
         Ethics and medical professionalism

Documents
Mandatory COVID-19 vaccination of health care workers

https://policybase.cma.ca/link/policy14449

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health human resources
Population health, health equity, public health

Documents

https://policybase.cma.ca/link/policy14443

POLICY TYPE  Policy endorsement

DATE  2021-06-24

TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Population health, health equity, public health

Documents


INTRODUCTION

Current policy is based on an unjustified understanding of science and perpetuates harm to individuals, communities, and society. Policy change is essential to promote health, reduce stigma, and support harm reduction and other evidence-based approaches. This policy brief is intended to support this change.

This policy brief is based on the following evidence:

-  Consensus statement on networks for high-quality rural anesthesia, surgery, and other medical care.
-  CMA Policybase - Canadian Medical Association

1. **Evidence of Harm:**
   -  The decriminalization of drug use and possession for personal use is associated with reduced harms to individuals, communities, and society.
   -  Criminalization of drug use and possession for personal use results in increased stigma, discrimination, and police intervention, which can lead to increased harm.
   -  Evidence suggests that decriminalization is associated with reduced rates of drug-related mortality, overdose deaths, and HIV transmission.

2. **Evidence of Effectiveness:**
   -  Decriminalization is a harm reduction strategy that can be implemented alongside other evidence-based approaches.
   -  It is associated with reduced rates of drug-related harms, including overdose deaths, HIV transmission, and criminal justice involvement.

3. **Evidence of Public Support:**
   -  Public opinion surveys and community engagement initiatives have consistently shown strong support for decriminalization of drug use and possession for personal use.

4. **Evidence of International Experience:**
   -  Countries that have decriminalized drug use and possession for personal use have reported reductions in drug-related harms, increased access to treatment, and improved health outcomes.

Conclusions:

-  The decriminalization of drug use and possession for personal use is a necessary step towards reducing harm and promoting health.
-  This policy brief supports evidence-based approaches to drug policy that aim to minimize harms and support individuals and communities.

Endorsement:

The Canadian Medical Association endorses this policy brief and calls for action to support decriminalization of drug use and possession for personal use. This includes advocating for legal reform, investing in harm reduction programs, and promoting health equity.

CMA Policybase - Canadian Medical Association
Consensus statement on networks for high-quality rural anesthesia, surgery, and obstetric care in Canada

https://policybase.cma.ca/link/policy14477

**POLICY TYPE**
Policy endorsement

**DATE**
2021-05-17

**TOPICS**
Health systems, system funding and performance
Health human resources
Valuing Caregivers and Recognizing Their Contribution to Quebec’s Health System

https://policybase.cma.ca/link/policy14373

POLICY TYPE: Parliamentary submission
DATE: 2020-09-29
TOPICS: Health human resources
Health systems, system funding and performance

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE        2020-08-13
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Dear [Name],

We are writing to raise a matter that is of significant concern to medical professionals in Canada. In light of the ongoing COVID-19 pandemic, we are facing unprecedented challenges in terms of drug shortages and supply chain disruptions.

As you are aware, the pharmaceutical and medical communities have been hit hard by the global crisis, with shortages of essential medications and medical supplies. This has led to a situation where healthcare providers are being forced to ration treatments and make tough decisions about which patients receive critical care.

We are concerned that the current situation is not only affecting our ability to provide care but also undermining the trust and confidence of the public in our healthcare system. The potential for further escalations in this crisis is inevitable unless we see immediate and decisive action from all levels of government.

At this time, we believe that the federal government is in the best position to address this crisis. We urge you to consider the following actions:

1. Immediate provision of financial support to pharmaceutical companies to maintain production and supply.
2. Implementation of a national strategy to ensure a consistent supply of essential medications.
3. Collaboration with international partners to share resources and expertise in dealing with shortages.
4. Enhanced monitoring and reporting of drug shortages to facilitate timely intervention.

We are committed to working closely with all stakeholders to find solutions to this pressing issue. We believe that together, we can overcome this challenge and ensure that all Canadians have access to the care they need.

Thank you for your attention to this matter.

Sincerely,

[Your Name]
[Your Position]
[Your Contact Information]
Protecting and supporting Canada’s health-care providers during COVID-19

https://policybase.cma.ca/link/policy14260

POLICY TYPE
Parliamentary submission

DATE
2020-03-23

TOPICS
Physician practice, compensation, forms
Health systems, system funding and performance
Health human resources

Documents

March 23, 2020

Dear Dr. Anna Tamura

Chair, Canadian Medical Association
10055-60 Avenue
Edmonton, AB T6H 1R8

Dear Dr. Tamura,

We are writing to offer our support to Canadian health-care providers during the COVID-19 pandemic. We understand the public health measures put in place to contain the virus are critical to slowing the spread and preventing overloading the health-care system. However, we must ensure there is ample access to quality health care for all Canadians.

We are committed to ensuring that all health-care providers have the necessary resources to deliver care. We have asked the federal government to provide financial support to health-care providers, including physicians and nurses, to ensure they have the resources they need to care for patients.

We are also asking the provinces and territories to provide financial support to health-care providers, including physicians and nurses, to ensure they have the resources they need to care for patients.

We are aware of the challenges that health-care providers are facing. We are working with the federal government to ensure that they have the necessary resources to deliver care.

Sincerely,

[Signature]

Canadian Medical Association

[Logo]
Flexibility in Medical Training (Update 2009)

Policy document

Last reviewed: 2020-02-29

Date: 2009-05-31

Replaces: Flexibility in Medical Training

Topics: Health human resources

CMA Policybase - Canadian Medical Association
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2019-05-24</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

**Documents**

![CMA response:]

HEALTH CANADA CONSULTATION ON REDUCING YOUTH ACCESS AND APPEAL OF VAPING PRODUCTS

May 24, 2019
Standing Committee on Health’s study on violence faced by healthcare workers
https://policybase.cma.ca/link/policy14052

POLICY TYPE
Parliamentary submission

DATE
2019-05-14

TOPICS
Health care and patient safety
Ethics and medical professionalism
Health human resources
Physician practice, compensation, forms

Documents
Scopes of practice
https://policybase.cma.ca/link/policy1237

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2002-01-22
TOPICS  Health human resources

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

Cannabis for Medical Purposes

Cannabis is a natural product that is recognized as a Schedule I drug under the Controlled Drugs and Substances Act. Multiple provinces have explored the idea of providing patients with access to cannabis for medical purposes. The following is the Canadian Medical Association's position on cannabis for medical purposes.

The Canadian Medical Association (CMA) recognizes the use of cannabis by individuals who suffer from terminal illness or chronic disease for which conventional treatments have not been effective or are considered inappropriate.

Physicians have a moral obligation to support patients who choose to use cannabis for medical purposes. They should, on request, provide a medical certificate for cannabis use in cases where the patient requests such documentation for legal purposes, and be prepared to discuss the potential benefits and risks of cannabis use with patients.

The CMA recommends the following recommendations:

1. Support the advancement of scientific knowledge about the medical use of cannabis. The CMA recommends funding to support research into cannabis, including its safety, efficacy in treating various conditions, and interactions with other medications.
2. Support the establishment and enforcement of regulations to control access to cannabis for medical purposes.
3. Support the development of educational programs to inform patients, health care providers, and the public about the use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recommends that health care providers have access to accurate and reliable information about the use of cannabis for medical purposes.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.

The CMA encourages patients to discuss their use of cannabis with their health care providers to ensure safe and effective use.

The CMA recognizes the potential for cannabis to be used as a treatment for certain medical conditions, and encourages further research to determine its efficacy and safety.

The CMA supports the development of policies and guidelines to promote the safe and effective use of cannabis for medical purposes.
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2012-12-08

TOPICS
Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents